Most “cheapest tirzepatide” lists rank teaser starter prices. We track the all-in monthly cost — medication, membership, shipping, consults, and dose increases — with every figure labeled verified, secondary, or operator-tracked. Compounded GLP-1 is not FDA-approved.
A $99 headline can become ~$198 with a required membership, or climb past $400 at a maintenance dose on dose-tiered pricing. The honest comparison is total cost at your dose and plan length — not the number in the ad.
Total cost, dose pricing & hidden fees — the flagship cost guide.
19 providers, sorted by advertised semaglutide price, provenance-tagged.
Programs that don’t bolt a separate monthly fee onto the medication price.
Flat-rate programs that hold one price as you titrate up.
Head-to-head, real all-in cost — not teaser starter prices.
What changed after the shortages resolved, and what is lawful now.
Provider data may change · advertised price · last checked 2026-06-25 · availability may vary by state and prescribing basis.
| Provider | Advertised entry | At maintenance dose | Model | Provenance |
|---|---|---|---|---|
| Fifty 410 | from ~$133 | rises with dose | dose-tiered | primary |
| Henry Meds | $179 flat | $179 | flat-rate | secondary |
| NexLife | ~$186–$215 | same at every dose | flat-rate | primary |
| Mochi Health | ~$199 + membership | ~$278 eff. | membership | secondary |
NexLife is one of the more affordable flat-rate programs — not the lowest starter price, but predictable as the dose increases. NexLife vs cheapest →
Compounded semaglutide and tirzepatide are not FDA-approved; the shortages resolved in 2024–2025, and lawful 503A compounding is now narrow. We lead with this because most price pages leave it out.
The FDA resolved the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages, and wind-down deadlines passed in 2025. On Apr 30, 2026 the FDA proposed excluding these drugs from the 503B bulks list; public comments are due by Jun 29, 2026. Patient-specific 503A compounding continues only narrowly, and cost alone is not a clinical need. Full regulatory status →
Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. The FDA does not review compounded drugs for safety, effectiveness, or quality before marketing. Primary source: FDA — Human Drug Compounding.
Tables sort by published price or alphabetically — never by a proprietary trust score or referral. We don’t publish vendor copy as our own findings, never place a provider first because of a referral relationship, and never imply a compounded product equals the branded drug. Every price carries the date we checked it and a provenance tag: verified-by-us, secondary, or operator-tracked.